China’s National Health Commission Launches “Silver‑Haired” Healthcare & Elderly‑Care Initiative
Policy / Regulatory

China’s National Health Commission Launches “Silver‑Haired” Healthcare & Elderly‑Care Initiative

China’s National Health Commission Issues “AI + Healthcare” Implementation Opinions – Roadmap for 24 Standardized Applications
Policy / Regulatory

China’s National Health Commission Issues “AI + Healthcare” Implementation Opinions – Roadmap for 24 Standardized Applications

Zhejiang Acea Pharma Secures Conditional NMPA Approval for Olgotrelvir Sodium Capsules – First Dual‑Target COVID‑19 Oral Antiviral in China
CompanyDrug

Zhejiang Acea Pharma Secures Conditional NMPA Approval for Olgotrelvir Sodium Capsules – First Dual‑Target COVID‑19 Oral Antiviral in China

Daiichi Sankyo’s Enhertu Wins CDE Acceptance for First‑Line HER2‑Positive Breast‑Cancer Indication in China
CompanyDrug

Daiichi Sankyo’s Enhertu Wins CDE Acceptance for First‑Line HER2‑Positive Breast‑Cancer Indication in China

Metsera Faces Escalating Bidding War as Novo Nordisk’s $10 B Offer Tops Pfizer’s Revised Proposal
CompanyDeals

Metsera Faces Escalating Bidding War as Novo Nordisk’s $10 B Offer Tops Pfizer’s Revised Proposal

Roche Announces a $55 M Partnership with Manifold Bio to Build BBB Shuttles
CompanyDeals

Roche Announces a $55 M Partnership with Manifold Bio to Build BBB Shuttles

Eli Lilly Announces Phase 3 ATTAIN‑PAD Trial for Oral GLP‑1 Agent orforglipron
CompanyDrug

Eli Lilly Announces Phase 3 ATTAIN‑PAD Trial for Oral GLP‑1 Agent orforglipron

Green Valley Faces Bribery Fine as Re‑registration Deadline Passes
Company

Green Valley Faces Bribery Fine as Re‑registration Deadline Passes

CARsgen Therapeutics Shares Promising Early Results for Allogeneic CAR‑T Products
CompanyDrug

CARsgen Therapeutics Shares Promising Early Results for Allogeneic CAR‑T Products

Guangzhou’s 12‑Step Plan to Accelerate Innovative Drug and Device Adoption
Policy / Regulatory

Guangzhou’s 12‑Step Plan to Accelerate Innovative Drug and Device Adoption

Hengrui Gets NMPA Green Light for Rezvilutamide‑HS‑20093 Combination Trial in Prostate Cancer
CompanyDrug

Hengrui Gets NMPA Green Light for Rezvilutamide‑HS‑20093 Combination Trial in Prostate Cancer

CStone Receives NMPA Approval for CS2009 Phase II Trial in Advanced Solid Tumors
CompanyDrug

CStone Receives NMPA Approval for CS2009 Phase II Trial in Advanced Solid Tumors